Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin. The New England journal of medicine Palmer, A. C., Kurtz, D. M., Alizadeh, A. A. 2023; 389 (8): 764-766

View details for DOI 10.1056/NEJMc2306105

View details for PubMedID 37611128